The DOI matches its Crossref record; 59 of the 61 references it cites were found in a registry or an index.
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer
Open accessAbstract
Significance: There are no effective therapies currently available for advanced pancreatic cancer. We show that there are two populations of cancer cells within a pancreatic tumor that require targeting by different metabolic inhibitors for effective tumor control. Rapidly dividing cells use glutamine, and can be effectively killed by administration of a nanoparticle containing an inhibitor of glutamine metabolism. Hypoxic cells, which are slowly dividing cells, metabolize glucose and can be targeted by metformin, a drug used for the treatment of diabetes. Clinical trials are needed to determine whether combination therapy, with drugs that effectively block the metabolism of glutamine and glucose, improves the survival of patients with pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“pancreatic tumor-initiating cells have been found to preferentially utilize mitochondrial metabolism, as compared to glycolytic metabolism preferred by bulk tumor cells244.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [244]
Citations
Cites
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
HMDB: the Human Metabolome Database
Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl923 · Cited by 3,219
From genomics to chemical genomics: new developments in KEGG
Kanehisa, M. I. (2005) · Nucleic Acids Research · doi:10.1093/nar/gkj102 · Cited by 3,126
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Jagt, D. L. V., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,528
Self-citationEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Reactome: a knowledgebase of biological pathways
Joshi-Tope, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki072 · Cited by 1,291
Cited by
Sorted by citations
Items 201–238 of 238
The application prospects of amino acid deprivation for cancer therapy
Meng, W., Wang, R., Peng, J., Li, Z., Ali, A. R., Bian, J., Huang, H., & Tian, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118705 · Cited by 3
Paul, A., Biswas, A., Chatterjee, S., Raj, A., Raychaudhuri, R., Mutalik, S., & Alex, A. T. (2023) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-023-09785-8 · Cited by 2
“The combination of metformin along with BPTES nanoparticles led to a much higher reduction in pancreatic tumor size than either treatment alone in pancreatic cancer [23].”
InfluentialDammen‐Brower, K., Arbogast, O., Zhu, S. E., Qiu, C., Zhang, C., Khare, P., Le, A., Jia, X., & Yarema, K. J. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214144 · Cited by 2
Self-citationHou, W., Fang, J., Su, L., Ye, H., & Ruan, B. H. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.014 · Cited by 2
Anzmann, A. F., Carney, O. S., Pado, A. M., Busa, V. F., Vaz, F. M., Kreimer, S. D., Cole, R. N., Le, A., Kirsch, B. J., Claypool, S. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.06.425502 · Cited by 2
“Metabolites within the cell pellet were extracted with 80% HPLC-grade methanol (Fisher 550 Scientific) and 20% mass-spec (MS)-grade water as previously described (54).”
MethodSelf-citationDesigning metabolic target-specific inhibitors for cancer therapy
Singh, T., Kharat, A. S., Rathi, B., & Kumar, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99879-6.00011-0 · Cited by 1
Tatar, C., & Erdemir, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107499 · Cited by 1
Glutamine homeostasis regulates PD-L1 level through STAT3 in pancreatic cancer
Li, Z., Otkur, W., Qi, H., Li, J., Li, S., Ling, T., Wang, H., Li, R., Zhang, Q., Sun, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102092 · Cited by 1
Glutamine alleviates Staphylococcus aureus-induced mastitis by modulating macrophage polarisation
Feng, C., Liu, M., He, Z., Liu, Y., Yuan, W., Xie, P., Zhao, C., Hu, X., Fu, Y., Han, F., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014053 · Cited by 1
“To demonstrate that α KG plays a central role in alleviating mastitis, we injected BPTES (10 mg/kg, i.p. [23]), a GLS 1 inhibitor, while administering glutamine via oral gavage to mice.”
Self-citationWang, F., Huang, M., Sheng, K., Yan, Y., Zhang, B., Wang, X., Yang, Z., Li, M., Liu, Y., Qi, Q., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03765-1 · Cited by 1
“Conversely, tumor cells can augment glycolysis to compensate for growth inhibition caused by glutaminolysis inhibitors [11].”
Self-citationPolymeric nanoparticles in cancer therapy
Shetty, N. S., & Satyaprasad, A. U. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99690-7.00013-3 · Cited by 1
Din, Z. U., Khan, Y., Zia, A., Anbreen, N., & Sultan, R. (2023) · Advances In Clinical And Medical Research · doi:10.52793/acmr.2023.4(3)-61
Simón, J., Núñez-García, M., Fernández‐Tussy, P., Barbier‐Torres, L., Fernández‐Ramos, D., Gómez‐Santos, B., Buqué, X., Lopitz‐Otsoa, F., Zubiete‐Franco, I., Juan, V. G., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3219265 · Cited by 1
Tumor metabolic reprogramming in therapeutic resistance
Siegel, P. M., & Ursini‐Siegel, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00005-x · Cited by 1
Glutamine metabolism in prostate cancer
Koltai, T., Reshkin, S. J., Baltazar, F., & Fliegel, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90528-2.00001-1
Glutamine is required for M1-like polarization in response to Mycobacterium tuberculosis infectionPreprint
Jiang, Q., Qiu, Y., Kurland, I. J., Drlica, K., Subbian, S., Tyagi, S., & Shi, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.11.475775
Sunami, Y. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_13
Funderburg, N. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735291597.793566589
Developing New Cancer Nanomedicines by Repurposing Old Drugs
Yang, B., & Shi, J. (2020) · Angewandte Chemie · doi:10.1002/ange.202004317
Galli, T. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735525717.793562709
Targeting the Immuno-Oncology Metabolism in Cancer
Tripathi, S. C., Fahrmann, J. F., & Amle, D. B. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_5
Synergistic Effects of Glutamine Deprivation and Metformin in Acute Myeloid Leukemia
Liu, T.-Y., Fu, X., Yang, Y., Gu, J., Xiao, M., & Li, D. (2024) · Current Medical Science · doi:10.1007/s11596-024-2913-z
Zou, B., Williams, J., Landau, M. B., Lin, W., Fell, S., Yang, Z., Jones, M., Blair, R., Steele, C. H., Khare, P., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114112
Self-citationRole of Nanotechnology in Pancreatic Cancer
Lokeshwari, B., Divya, M., Subhalakshmi, U., & Prakathi, P. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-1469-3.ch004
Global profiling of protein lactylation in pancreatic ductal adenocarcinoma
Toledo, D., Oluwole, S. A., Owiredu, S., Carr, G., & Agatemor, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-43771-7
“Such variability is consistent with metabolic heterogeneity recognized in PDAC 75–77 .”
Khawkhiaw, K., Lert-itthiporn, W., Seyedasli, N., Chiu, C., & Saengboonmee, C. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i13.115536
Glutamine Metabolism: Role in Cancer Cell Proliferation and Survival
Chakraborty, A. J., Pramanik, S., Mullick, S., Nath, R., Mondal, M., Pal, R., Ashique, S., & Jana, M. (2026) · Cancer treatment and research · doi:10.1007/978-3-032-21861-2_3
Metabolic plasticity in the pancreatic cancer metastatic cascade
Zhu, B., Guo, Y., & Lu, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189622 · Cited by 1
Bhongade, B. A., Ali, A. A., El‐Tanani, M., Satyam, S. M., Talath, S., Wali, A. F., Rabbani, S. A., Ibraheem, W., Hoffmann, K., Арманович, А. А., et al. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070723
“For example, the combination of glutaminase inhibitors with autophagy inhibitors or glucose metabolism blockade has demonstrated synergistic activity in preclinical models [11,96].”
Metabolic Reprogramming in Cancer and Therapeutic Implications
Singh, S., Desai, U., Goswami, D., Barnwal, A., Domadia, D., Thakur, S., & Premi, S. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_5
Peng, X., Liu, S., & Tao, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00812-1
Advances and Hurdles of PLGA-Based Therapy for Pancreatic Cancer
Al‐Nemrawi, N. K., AbuAlna’aj, G. M., Hazaimeh, R. A. A., Al-Quraan, S. A., Yaseen, N. A. B., Hameedat, F., & de Sousa, F. A. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03508-1
Shao, D., Song, J., & Wang, J. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103188
Glutamine metabolism in health and disease
Zhao, J., Lin, Y., Gao, R., Gao, H., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02981-1
BindingDB (2021) · UC San Diego · doi:10.7270/q26t0qz0
Metadata
- Authors
- Elgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., Neisser, M., Nguyen, C., Lee, R., Park, J. K., Reyes, J., Hartung, T., Rojas, C., Rais, R., Tsukamoto, T., Semenza, G. L., Hanes, J., Slusher, B. S., & Le, A.
- Affiliations
- Johns Hopkins University (US)
- Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-08-24
- Volume
- 113
- Issue
- 36
- Pages
- E5328-36
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5018752
- OpenAlex
- W2515129893
- Cited by
- 234
- References
- 61
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 17 · 2023: 25 · 2022: 24 · 2021: 38 · 2020: 32 · 2019: 19 · 2018: 21 · 2017: 21 · 2016: 1
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (R01-CA193895, R21-CA169757)
- HHS | NIH | National Institute on Drug Abuse (R03-DA032470)
- HHS | NIH | National Institute of Mental Health (P30-MH075673)
- HHS | NIH | National Center for Advancing Translational Sciences (UL1-TR001079)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- BPTES, glutaminase inhibition, glutamine metabolism, pancreatic cancer, nanoparticles, drug encapsulation, metformin, combination therapy, tumor metabolic heterogeneity, tumor hypoxia, glycolysis, glycogen synthesis, CB-839, pharmacokinetics, cancer metabolism
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Glutaminase, Glutamine, Humans, Metformin, Pancreatic Neoplasms, Sulfides, Thiadiazoles, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Benzeneacetamides, Cell Line, Tumor, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
